Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 14,245 shares, a decline of 50.6% from the July 30th total of 28,818 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 345,411 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

CHGCY has been the subject of a number of analyst reports. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Get Chugai Pharmaceutical alerts:

View Our Latest Research Report on CHGCY

Chugai Pharmaceutical Stock Performance

CHGCY stock opened at $21.82 on Monday. The firm has a 50 day moving average of $22.25 and a 200-day moving average of $25.41. The company has a market cap of $71.82 billion, a price-to-earnings ratio of 23.72 and a beta of 0.60. Chugai Pharmaceutical has a 12-month low of $20.43 and a 12-month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The business had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Sell-side analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

Read More

• Five stocks we like better than Chugai Pharmaceutical
• Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
• Rubrik’s AI Security Bet Could Power the Next Leg Higher
• Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
• Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.